Literature DB >> 19259290

Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Jonathan R Strosberg1, Aejaz Nasir, Pamela Hodul, Larry Kvols.   

Abstract

Neuroendocrine malignancies of the gastroenteropancreatic axis include carcinoid and pancreatic endocrine tumors. These heterogeneous neoplasms arise from the enterochromaffin cells of the gastrointestinal tract and the islet cells of the pancreas. Histologically, most well-differentiated endocrine tumors consist of small, round, monomorphic cells, arranged in islands or trabeculae, with a distinct "salt-and-pepper" pattern of nuclear chromatin. Chromogranin and synaptophysin are useful as immunohistochemical markers of neuroendocrine differentiation. Other common features include the capacity to secrete peptide hormones and biogenic amines. A relatively indolent growth rate is characteristic of most gastrointestinal neuroendocrine tumors, with the exception of poorly differentiated tumors which are usually aggressive. Treatment strategies are designed to limit tumor progression and palliate hormonal syndromes. This article reviews the diverse biologic characteristics of gastrointestinal neuroendocrine tumors and current treatment options for metastatic disease.

Entities:  

Year:  2008        PMID: 19259290      PMCID: PMC2633071     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  227 in total

1.  Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome.

Authors:  A THORSON; G BIORCK; G BJORKMAN; J WALDENSTROM
Journal:  Am Heart J       Date:  1954-06       Impact factor: 4.749

2.  Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine.

Authors:  V ERSPAMER; B ASERO
Journal:  Nature       Date:  1952-05-10       Impact factor: 49.962

Review 3.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 4.  Imaging advances in the diagnosis of endocrine neoplasia.

Authors:  B A Scott; R A Gatenby
Journal:  Curr Opin Oncol       Date:  1998-01       Impact factor: 3.645

5.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

6.  Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden.

Authors:  K Hemminki; X Li
Journal:  Int J Cancer       Date:  2001-11-01       Impact factor: 7.396

7.  Prognosis of carcinoid heart disease: analysis of 200 cases over two decades.

Authors:  Jacob E Møller; Patricia A Pellikka; Alain M Bernheim; Hartzell V Schaff; Joseph Rubin; Heidi M Connolly
Journal:  Circulation       Date:  2005-11-14       Impact factor: 29.690

8.  Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.

Authors:  P Ruszniewski; M Ducreux; J A Chayvialle; J Blumberg; D Cloarec; H Michel; J M Raymond; J L Dupas; H Gouerou; R Jian; E Genestin; P Bernades; P Rougier
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

9.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

Review 10.  Zollinger-Ellison syndrome. Current concepts in diagnosis and management.

Authors:  M M Wolfe; R T Jensen
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

View more
  29 in total

1.  Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration.

Authors:  Nikki A Evensen; Cem Kuscu; Hoang-Lan Nguyen; Kevin Zarrabi; Antoine Dufour; Pournima Kadam; You-Jun Hu; Ashleigh Pulkoski-Gross; Wadie F Bahou; Stanley Zucker; Jian Cao
Journal:  J Natl Cancer Inst       Date:  2013-08-29       Impact factor: 13.506

2.  A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

Authors:  J R Strosberg; J M Weber; J Choi; T L Campos; T L Valone; G Han; M J Schell; L K Kvols
Journal:  Ann Oncol       Date:  2012-02-08       Impact factor: 32.976

3.  Neuroendocrine tumors: is there a standard treatment?

Authors:  Matthew H Kulke
Journal:  Gastrointest Cancer Res       Date:  2008-05

Review 4.  Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

Authors:  Jonathan R Strosberg; George A Fisher; Al B Benson; Lowell B Anthony; Bulent Arslan; John F Gibbs; Edward Greeno; Renuka V Iyer; Michelle K Kim; William J Maples; Philip A Philip; Edward M Wolin; Dasha Cherepanov; Michael S Broder
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 5.  Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Authors:  Michael S Lee; Bert H O'Neil
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 6.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 7.  Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy.

Authors:  Evan D Lehrman; Nicholas Fidelman
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

8.  Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma.

Authors:  Man Li; Yanjun Gu; Zhiguang Zhang; Shiwu Zhang; Danfang Zhang; Ali F Saleem; Xiulan Zhao; Baocun Sun
Journal:  Pathol Oncol Res       Date:  2009-12-17       Impact factor: 3.201

9.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

Review 10.  Evolving treatment strategies for management of carcinoid tumors.

Authors:  Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.